Pfizer and six British universities, including Cambridge and Oxford, have reached an agreement to collaborate in the search for drugs to treat diseases affecting less than 0.1% of the population. More than 6,000 such rare diseases are recognized worldwide, and the majority are thought to be gene-based.

Full Story:

Related Summaries